levels. Semen samples were collected at the beginning and end of the study EOS). Testicular volume was measured at baseline and 16 weeks of treatment as determined by orchidometry. Serum samples, collected at baseline and 16 weeks, were analyzed for hormone and lipid levels.
levels. Semen samples were collected at the beginning and end of the study EOS). Testicular volume was measured at baseline and 16 weeks of treatment as determined by orchidometry. Serum samples, collected at baseline and 16 weeks, were analyzed for hormone and lipid levels.
RESULTS: Results: TT levels were increased between baseline and after 16 weeks of treatment in all treatment groups. EC administration reestablished a more normal diurnal pattern of secretion. FSH and LH levels increased in the EC groups and decreased in the AG group at 16 weeks. EC maintained sperm concentration in the normal range over the treatment period. In contrast there was a marked reduction in spermatogenesis in the AG group. Combined data from the two studies showed normalized morphology strict was significantly improved with EC administration and decreased with AG administration. All men were similar at baseline in testes volume (p ¼ 0.94, ANOVA) by orchidometry. In both studies men on topical testosterone demonstrated decreases in mean testicular volume (-0.86 cm3) and a significant decrease overall compared to the EC (p<0.05) or placebo (p<0.05). Treatment with daily oral enclomiphene citrate lowered serum cholesterol by 18.1 mg/dL over 16 weeks.
CONCLUSIONS: Conclusions: EC consistently increased serum TT, LH and FSH restoring normal levels of serum testosterone. The effects on TT were also seen with T replacement, via AG, but sperm counts were not maintained and in most cases decreased. EC treatment maintained sperm concentrations in the normal range and morphology strict parameters were improved. EC resulted in a significant increase in testicular volume, whereas treatment with AG resulted in a significant decrease in testicular volume. A significant decrease in cholesterol was seen with EC.
Source of Funding: Repros Therapeutics

MP81-09 THE NERVES IN THE GLANS PENIS: ANATOMICAL AND HISTOLOGICAL STUDY
Nobuyuki Hinata*, Kobe, Japan; Ahmed Aly Hussein, Buffalo, NY; Tomoaki Terakawa, Yukari Bando, Kobe, Japan; Gen Murakami, Iwamizawa, Japan; Khurshid Guru, Buffalo, NY; Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: The topographical anatomy of the composite nerve fibers in the human glans penis is poorly characterized. Therefore, histological methods were used to analyze nerves to the cavernous tissue at the distal end of the corpus spongiosum.
METHODS: Immunohistochemical techniques were used to detect S100, neuronal nitric oxide synthase, tyrosine hydroxylase, and vasoactive intestinal polypeptide protein expressions in frontal or sagittal penile sections obtained from 20 donated, older male cadavers.
RESULTS: At or near the coronal sulcus at the dorsal midline, three to seven terminal branches of the unilateral dorsal nerve ran deeply or centrally along the distal dull end of the corpus cavernosum and entered the glans cavernous tissue. Once there, the nerve divided into thinner branches (neuronal nitric oxide synthase or tyrosine hydroxylase positive) and the major nerve section reached the surface skin of the glans. Several thin nerves took highly arduous paths, as evidenced in ventral subcutaneous tissue of the distal third of the penis.
CONCLUSIONS: Histological examination revealed a neurovascular bundle that penetrated the glans cavernous tissue toward the skin covering, with a rich nerve supply to the skin folds at and near the coronal sulcus. (Dusseldorf, Hannover, Heidelberg, Munich) were invited within a screening trial. 10.135 Caucasian, heterosexual and sexually active men were included in this analysis. An anamnesis interview was obtained for all men including information on comorbidities and medication. Weight and waist circumference were measured on site. Erectile function was evaluated using the International Index of Erectile Function (IIEF-EF(6)). The presence of ED was defined as IIEF-EF-Score <¼25. Association of ED and comorbidities/risk factors were analyzed by logistic regression.
RESULTS: The prevalence of ED was 25.2% (IIEF-EF: 6-10: 3.1%, 11-16: 9.2%, 17-21: 4.2%, 22-25: 8.7%). We ascertained a baseline risk of 14.4% for men without ED-related comorbidities and with healthy lifestyle factors: no smoking, waist circumference <94cm, physical activity >¼4 days a week, IPSS¼0. In multiple logistic regression with backward elimination the following factors associated with ED were identified: Comorbidities: Depression [OR 1.87], lower urinary tract symptoms (defined as International Prostate Symptom e1092 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
